It seems to me that the Wikipedia mechanism works wonderfully well.  One
rule is that you can't make assertions yourself, only report pre-existing
material that is attributable to a "reliable published source".

It's immediately obvious when something is controversial.  Here's the first
para of the entry on statins, which are currently being debated in the UK:

*Statins* (or *HMG-CoA reductase inhibitors*) are a class of
drugs<http://en.wikipedia.org/wiki/Drugs> used
to lower cholesterol <http://en.wikipedia.org/wiki/Cholesterol> levels by
inhibiting <http://en.wikipedia.org/wiki/Enzyme_inhibitor> the enzyme HMG-CoA
reductase <http://en.wikipedia.org/wiki/HMG-CoA_reductase>, which plays a
central role in the production of cholesterol in the
liver<http://en.wikipedia.org/wiki/Liver>,
which produces about 70 percent of total cholesterol in the body. Increased
cholesterol levels have been associated with cardiovascular
disease<http://en.wikipedia.org/wiki/Cardiovascular_disease>
(CVD).[1] <http://en.wikipedia.org/wiki/Statins#cite_note-1> Statins have
been found to prevent
<http://en.wikipedia.org/wiki/Preventive_medicine> cardiovascular
disease in those who are at high risk. The evidence is strong that statins
are effective for treating CVD in the early stages of a disease (secondary
prevention <http://en.wikipedia.org/wiki/Secondary_prevention>). The
evidence is weaker that statins are effective for those with elevated
cholesterol levels but without CVD (primary
prevention<http://en.wikipedia.org/wiki/Primary_prevention>
).[2] 
<http://en.wikipedia.org/wiki/Statins#cite_note-NICEquick-2>[3]<http://en.wikipedia.org/wiki/Statins#cite_note-Cochrane13-3>
[4] <http://en.wikipedia.org/wiki/Statins#cite_note-Cochrane11-4> Side
effects of statins include muscle pain, increased risk of
diabetes<http://en.wikipedia.org/wiki/Diabetes> and
abnormalities in liver enzyme
tests<http://en.wikipedia.org/wiki/Liver_function_tests>
.[5] <http://en.wikipedia.org/wiki/Statins#cite_note-Naci2013-5> Additionally,
they have rare but severe adverse effects, particularly muscle
damage.[6]<http://en.wikipedia.org/wiki/Statins#cite_note-Jacob2011-6>
Some
doctors believe that statins are over-prescribed.

(Could Proteopedia adopt a style that is closer to that?)




On 15 May 2014 15:35, Bernhard Rupp <[email protected]> wrote:

> Maybe  a prominent link in the summary page of e.g. PDBe 2a01 would help.
>
> So far, you need to go there  and expand Links -> pdb_redo -> links ->
>  Proteopedia to get to the corresponding warning.
>
> http://www.ebi.ac.uk/pdbe-srv/view/entry/2a01/summary_details.html#
>
> http://www.cmbi.ru.nl/pdb_redo/a0/2a01/index.html
>
> http://proteopedia.org/wiki/index.php/2a01
>
>
>
> ‘More information about this (or any) entry may be available in
> Proteopedia’
>
>
>
> Best, BR
>
>
>
> Ceterum censeo structurae Murthius delendati erunt.
>
>
>
> (Marcus Tullius Raaijmakers)
>
>
>
> *From:* CCP4 bulletin board [mailto:[email protected]] *On Behalf Of *Joel
> Sussman
> *Sent:* Donnerstag, 15. Mai 2014 16:01
> *To:* [email protected]
> *Subject:* Re: [ccp4bb] PDB passes 100,000 structure milestone
>
>
>
> 15-May-2014
>
> Dear Martyn
>
>    Proteopedia's (*http://proteopedia.org <http://proteopedia.org>*) goal
> goes well beyond just education - it is aimed at Structural Biology and non
> Structural Biology Community and it would be pleased to be a forum for
> discussion of structures that are questionable. There are now over 2,600
> registered users, who are contributing to Proteopedia, in over 50 different
> countries.
>
>    *Proteopedia has a special area for discussions related to each
> structure*. *To access it, you go to the structure's page, e.g.
> http://proteopedia.org/w/2x24 <http://proteopedia.org/w/2x24>* and *click
> on the 'discussion' tab* on the page's upper border. Everyone can read
> the comments there, and it will open a fully editable page for every
> registered user to add *their comments on the structure and their full
> name will be listed below their comments.*
>
>    If you would like to contribute to this, we’d be pleased to welcome
> your input.
>
>    Best regards,
>
>    Jaime Prilusky & Joel Sussman
>
>
>
>
>
> On 15May, 2014, at 7:29, MARTYN SYMMONS <
> [email protected]> wrote:
>
>
>
> I agree some forum for community annotation and commenting would be a good
> thing for users of structural data.
>
> There was an attempt to do that with the pdbwiki project which was a
> community resource for the bioinformatics community. Unfortunately pdbwiki
> has now folded (see http://pdbwiki.org/) They are now directing people to
> Proteopedia. However Proteopedia has a more educative focus I think -
> rather than capturing technical questions and input.
>
>
>
> Pubmed commons (http://www.ncbi.nlm.nih.gov/pubmedcommons/), which is a
> forum for discussing the literature, is currently under testing. Perhaps
> this is the sort of thing that could work for structural data?
>
>
>
> cheers
>
>  Martyn
>
>
> ------------------------------
>
> *From:* Ethan A Merritt <[email protected]>
> *To:* [email protected]
> *Sent:* Wednesday, 14 May 2014, 19:22
> *Subject:* Re: [ccp4bb] PDB passes 100,000 structure milestone
>
>
> On Wednesday, 14 May, 2014 13:52:02 Phil Jeffrey wrote:
> > As long as it's just a Technical Comments section - an obvious concern
> > would be the signal/noise in the comments themselves.  I'm sure PDB
> > would not relish having to moderate that lot.
> >
> > Alternatively PDB can overtly link to papers that discuss technical
> > issues that reference the particular structure - wrong or fraudulent
> > structures are often associated with refereed publications that point
> > that out, and structures with significant errors often show up in that
> > way too.  I once did a journal club on Muller (2013) Acta Cryst
> > F69:1071-1076 and wish that could be associated with the relevant PDB
> > file(s).
>
> Perhaps some combination of those two ideas?
>
> The PDB could associate with each deposited structure  a crowd-sourced
> list of published articles citing it.    They already make an effort to
> attach the primary citation, but so far as I know there is currently
> no effort to track subsequent citations.
>
> While spam comments in a free-format forum are probably inevitable,
> spam submission of citing papers seems less likely to be a problem.
>
>     - Ethan
>
> > > On Wed, May 14, 2014 at 12:32 PM, Zachary Wood <[email protected]
> > > <mailto:[email protected]>> wrote:
> > >
> > >    Hello All,
> > >
> > >    Instead of placing the additional burden of policing on the good
> > >    people at the PDB, perhaps the entry page for each structure could
> > >    contain a comments section. Then the community could point out
> > >    serious concerns for the less informed users. At least that will
> > >    give users some warning in the case of particularly worrisome
> > >    structures. The authors of course could still reply to defend their
> > >    structure, and it may encourage some people to even correct their
> > >    errors.
> > >
> --
> Ethan A Merritt
> Biomolecular Structure Center,  K-428 Health Sciences Bldg
> MS 357742,  University of Washington, Seattle 98195-7742
>
>
>



-- 
 [email protected]    Douglas Instruments Ltd.
 Douglas House, East Garston, Hungerford, Berkshire, RG17 7HD, UK
 Directors: Peter Baldock, Patrick Shaw Stewart

 http://www.douglas.co.uk
 Tel: 44 (0) 148-864-9090    US toll-free 1-877-225-2034
 Regd. England 2177994, VAT Reg. GB 480 7371 36

Reply via email to